This provided the rationale for establishing phase I clinical trials to evaluate the safety, efficacy, and maximum tolerated dose of anti-CEA CAR-T-cell therapy in CEA-positive cancers, including lung cancer (NCT02349724 and NCT04348643). Here, CEACAM5 is linked to cancer.